We are committed to making a meaningful impact on patients' lives.
Our mission is to develop transformative medicines for orphan diseases of the kidney.
- Life-threatening Genetic Disease
- 4th Leading Cause of Kidney Failure
- No Approved Drug Treatments in the US
- Learn More
- Lixivaptan in Development for PKD
- Learn More
Please join Palladio Biosciences as we present the company and information about lixivaptan's development program for Autosomal Dominant Polycystic Kidney Disease during the Bio CEO & Investor Conference at the New York Marriott Marquis in New York City February 12-13, 2018.